The Use of a Single‐Pill Calcium Channel Blocker/Statin Combination in the Management of Hypertension and Dyslipidemia: A Randomized, Placebo‐Controlled, Multicenter Study
Open accessAbstract
Poor control of hypertension or dyslipidemia may at least in part be due to these risk factors being treated in isolation. The Caduet in Untreated Subjects Population (CUSP) trial was an 8‐week, randomized, double‐blind, placebo‐controlled trial evaluating the efficacy/safety of the combination of a calcium channel blocker (amlodipine besylate) and a statin (atorvastatin calcium) in a single‐pill form (5/20 mg) plus therapeutic lifestyle changes (TLC) compared with placebo plus TLC in patients with comorbid hypertension and dyslipidemia without evidence of cardiovascular disease. At week 4, additional antihypertensive/lipid‐lowering medication was permitted. The primary end point was the proportion of patients in whom the dual goal of blood pressure (<140/90 mm Hg) and low‐density lipoprotein cholesterol control (<100 mg/dL) was met at week 4. This dual goal attainment was significantly greater with amlodipine/atorvastatin plus TLC compared with placebo plus TLC at week 4 (47.6% vs 1.7%; P<.001), with further improvements at week 8. Most adverse events were mild to moderate. Therapy with single‐pill amlodipine/atorvastatin plus TLC in these patients significantly increased dual blood pressure/low‐density lipoprotein cholesterol goal attainment compared with placebo plus TLC.
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
Many cases of rhabdomyolysis resulting from statin use in combination with CYP substrates have been reported.
“Nonetheless, many cases of rhabdomyolysis resulting from statin use in combination with CYP substrates have been reported714).”
From Japan Atherosclerosis Society (JAS) guidelines for prevention of atherosclerotic cardiovascular diseases 2017 (2018) · cites this paper as [714]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Cites
Toprak, Ö., Kurt, H., Sarı, Y., Şarkış, C., Us, H., & Kırık, A. (2017) · Kidney & Blood Pressure Research · doi:10.1159/000468530 · Cited by 29,769 · see citing works
Grundy, S. M., Bilheimer, D. W., Chait, A., Clark, L. T., Denke, M. A., Havel, R. J., Hazzard, W. R., Hulley, S. B., Hunninghake, D. B., Kreisberg, R. A., et al. (1993) · JAMA · doi:10.1001/jama.269.23.3015 · Cited by 27,944 · see citing works
Expert Panel on Detection, E. (2001) · JAMA: The Journal of the American Medical Association · doi:10.1001/jama.285.19.2486 · Cited by 26,011 · see citing works
Chobanian, A. V., Bakris, G. L., Black, H. R., Cushman, W. C., Green, L. A., Izzo, J. L., Jones, D. W., Materson, B. J., Oparil, S., Wright, J. T., et al. (2003) · Hypertension · doi:10.1161/01.hyp.0000107251.49515.c2 · Cited by 13,271 · see citing works
Grundy, S. M., Cleeman, J. I., Merz, C. N. B., Brewer, H. B., Clark, L. T., Hunninghake, D. B., Pasternak, R. C., Smith, S. C., & Stone, N. J. (2004) · Circulation · doi:10.1161/01.cir.0000133317.49796.0e · Cited by 6,902 · see citing works
Grundy, S. M., Cleeman, J. I., Bairey Merz, C. N., Brewer, H. B., Clark, L. T., Hunninghake, D. B., Pasternak, R. C., Smith, S. C., & Stone, N. J. (2004) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2004.07.001 · Cited by 1,550 · see citing works
The Lipid Treatment Assessment Project (L-TAP)
Pearson, T. A., Laurora, I., Chu, H., & Kafonek, S. D. (2000) · Archives of Internal Medicine · doi:10.1001/archinte.160.4.459 · Cited by 1,012 · see citing works
Wong, N. D. (2007) · Archives of Internal Medicine · doi:10.1001/archinte.167.22.2431 · Cited by 233 · see citing works
Wong, N. D., López, V. A., Tang, S. S. K., & Williams, G. R. (2006) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2006.01.079 · Cited by 153 · see citing works
Hyre, A. D., Muntner, P., Menke, A., Raggi, P., & He, J. (2007) · Annals of Epidemiology · doi:10.1016/j.annepidem.2007.01.032 · Cited by 132 · see citing works
Prevalence of comorbid hypertension and dyslipidemia and associated cardiovascular disease.
Johnson, M. L., Pietz, K., Battleman, D. S., & Beyth, R. J. (2004) · PubMed · Cited by 127 · see citing works
Blank, R. C., LaSalle, J. R., Reeves, R. A., Maroni, J. M., Tarasenko, L. C., & Sun, F. (2005) · Journal of Clinical Hypertension · doi:10.1111/j.1524-6175.2005.04533.x · Cited by 73 · see citing works
Allison, T. G., Squires, R. W., Johnson, B. D., et al. (1999) · Mayo Clinic proceedings · doi:10.1097/00008483-200005000-00016 · Cited by 63 · see citing works
Flack, J. M., Victor, R. G., Watson, K. E., Ferdinand, K. C., Saunders, E., Tarasenko, L. C., Jamieson, M. J., Shi, H. H., & Bruschi, P. (2008) · Mayo Clinic Proceedings · doi:10.4065/83.1.35 · Cited by 54 · see citing works
Allison, T. G., Squires, R. W., Johnson, B. D., & Gau, G. T. (1999) · Mayo Clinic Proceedings · doi:10.4065/74.5.466 · Cited by 49 · see citing works
Allison, T. G., Squires, R. W., Johnson, B. D., & Gau, G. T. (1999) · Mayo Clinic Proceedings · doi:10.1016/s0025-6196(11)65124-0 · Cited by 38 · see citing works
Erdine, S. E., Ro, Y. S., Tse, H., Howes, L. G., Aguilar-Salinas, C., Chaves, H., Guindy, R. R., Chopra, P., Moller, R. A., Schou, I. M., et al. (2008) · Journal of Human Hypertension · doi:10.1038/jhh.2008.114 · Cited by 36 · see citing works
Rationale for multiple risk intervention: the need to move from theory to practice.
Erhardt, L. (2007) · PubMed Central · Cited by 14 · see citing works
A single-pill combination of amlodipine besylate and atorvastatin calcium
Blank, R. C. (2006) · Drugs of today · doi:10.1358/dot.2006.42.3.953593 · Cited by 13 · see citing works
A single-pill combination of amlodipine besylate and atorvastatin calcium (update)
Blank, R. C., Hobbs, R. F., Zamorano, J., et al. (2007) · Drugs of today · doi:10.1358/dot.2007.43.3.1079878 · Cited by 8 · see citing works
Flagged first, then by citations
Cited by
Sorted by citations
Kinoshita, M., Yokote, K., Arai, H., Iida, M., Ishigaki, Y., Ishibashi, S., Umemoto, S., Egusa, G., Ohmura, H., Okamura, T., et al. (2018) · Journal of Atherosclerosis and Thrombosis · doi:10.5551/jat.gl2017 · Cited by 813 · see citing works
- Authors
- Neutel, J. M., Bestermann, W. H., Dyess, E. M., Graff, A., Kursun, A., Sutradhar, S., & Yunis, C.
- Affiliations
- Orange County Research Center (US)
- Holston Valley Medical Center (US)
- Pfizer (United States) (US)
- Corresponding author
- Neutel, Joel M.
- ORCID
- Yunis, Carla
- Venue
- The Journal of Clinical Hypertension
- Publisher
- Wiley
- Published
- 2009-01
- Volume
- 11
- Issue
- 1
- Pages
- 22-30
- ISSN
- 1524-6175 (ISSN-L)
- 1751-7176
- PMC
- PMC8673228
- OpenAlex
- W1986897869
- Cited by
- 46
- References
- 21
- Citations by year
- 2025: 1 · 2024: 3 · 2023: 5 · 2022: 2 · 2021: 2 · 2020: 3 · 2019: 1 · 2018: 1 · 2017: 2 · 2016: 4 · 2015: 1 · 2014: 3 · 2013: 3 · 2012: 4
- FWCI
- 3.25
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- Journal of Clinical Hypertension (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Funders
- Sanofi
- Daiichi-Sankyo
- Daiichi Sankyo Europe
- Topics
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Blood Pressure and Hypertension Studies
- Health Sciences › Medicine › Surgery › Lipoproteins and Cardiovascular Health
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes, Cardiovascular Risks, and Lipoproteins
- Keywords
- amlodipine, atorvastatin calcium, fixed-dose combination, hypertension, dyslipidemia, LDL cholesterol control, blood pressure control, therapeutic lifestyle changes
- MeSH terms
- Atorvastatin, Analysis of Variance, Calcium Channel Blockers, Double-Blind Method, Drug Combinations, Female, Heptanoic Acids, Humans, Hypertension, Life Style, Male, Middle Aged, Placebos, Pyrroles, Treatment Outcome, Amlodipine, Hydroxymethylglutaryl-CoA Reductase Inhibitors, Dyslipidemias
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
